MALDEN, Mass., Sept. 18, 2021 /PRNewswire-PRWeb/ -- Vito
Lore, the VP of innovations at KICVentures Group, said "the patent
includes a device claim of our threaded implant with the fusion
channel; also an embodiment with a 3D porous structure."
"Clinically the 3D porous structure is expected to enhance the
threaded implant's performance in fixating the sacroiliac joint and
accelerating fusion," said Co-Inventor Dr Kingsley R. Chin, a Professor and
Board-Certified Orthopedic Spine Surgeon and acting CEO of Sacrix
LLC.
Sacrix LLC has pioneered a new percutaneous lateral-oblique
sacroiliac joint fusion technique that will now make it even easier
with the self-tapping, self-drilling and self-harvesting features
of this patented 3D porous threaded implant.
Sacrix LLC thanks the dedicated team of engineers, Oscar Herrera, Raul
Gawande, Darryl
Campbell-Spaulding, and industrial designer Josh Finkel as they worked with focus and
urgency to bring this landmark technology to our physicians and
patients.
About Sacrix LLC
Sacrix LLC is a KICVentures Group portfolio company focused on
revolutionary percutaneous lateral-oblique sacroiliac joint fusion
technologies for the treatment of sacroiliac dysfunction and
sacroiliitis. Sacrix developed its patented Sacrofuse threaded
implant to be inserted percutaneously and received FDA clearance in
2015. The Gen1 Sacrofuse implant was compared head-to-head with
market leader SI bone (SIBN) and found to have a 400% increase in
pull out strength. Sacrix has trained over 165 interventional pain
physicians to perform its revolutionary percutaneous
lateral-oblique sacroiliac joint fusion technique safely and
effectively through a 1.5 cm incision minimally invasively in
outpatient ambulatory surgery centers.
http://www.MySacrix.com
About KICVentures Group
Founded in 2000 makes us the most experienced healthcare investment
holding company with the largest portfolio of medical device
technologies focused on solutions for less invasive outpatient
spine surgery. Our investment strategy is to acquire or invent
disruptive technologies using our own capital or partner with
private individual investors. This allows us the freedom to make
quick and nimble decisions such as when we acquired AxioMed
Viscoelastic Disc Technologies while other firms invested in
ball-and-socket articulating spacers.
http://www.KICVentures.com
Media Contact
KICVentures Group, KICVentures Group, 267-342-3968,
Careers@KICVentures.com
SOURCE KICVentures Group